Leap Therapeutics to Host Conference Call to Provide DKN-01 Program Update
Conference Call Details
Leap management will be joined by the following DKN-01 clinical investigators:
Samuel J. Klempner , M.D., Assistant Professor,Tucker Gosnell Center for Gastrointestinal Cancers ,Massachusetts General Hospital Cancer Center andHarvard Medical School Rebecca C. Arend , M.D., Assistant Professor and Associate Scientist,Gynecologic Oncology Clinic , UAB Comprehensive Cancer Center Experimental Therapeutics Program
International Dial-in Number: (409) 231-2048
Conference ID: 3571417
The slides and audio webcast can also be accessed by visiting the Investors section of the Company's website at http://www.leaptx.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company's website for 30 days.
About
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include statements regarding Leap's expectations with respect to the development and advancement of DKN-01 and TRX518, including the initiation, timing and design of future studies, enrollment in future studies, business development, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the ability to complete a financing or form business development relationships to fund our expenses; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; our plans to research, develop, and commercialize our drug product candidates; our ability to achieve market acceptance of our drug product candidates; unanticipated costs or delays in research, development, and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially will be included in
CONTACT:
Chief Financial Officer
donsi@leaptx.com
617-714-0360
Investor Relations
212-600-1902
heather@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/leap-therapeutics-to-host-conference-call-to-provide-dkn-01-program-update-300889950.html
SOURCE